FDA Approves Eli Lilly's Jardiance For Heart Failure

The FDA approves Eli Lilly And Co LLY - Boehringer Ingelheim's Jardiance (empagliflozin) 10 mg for heart failure.
The approval comes to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).
Jardiance can be initiated in adults with HFrEF with an eGFR as low as 20 mL/min/1.73 m2.
The approval is based on results from the EMPEROR-Reduced Phase 3 trial.
In the trial, Jardiance significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25% (5.3% absolute risk reduction) versus placebo.
Related content: Benzinga's Full FDA Calendar.
Price Action: LLY shares are down 0.02% at $272.65 during the market session on the last check Wednesday.

Overview Rating:

Speculative

0100